At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial
In Brief
A Phase 4 clinical trial evaluating Teriparatide, calcium citrate, and 2 other interventions for Rheumatoid Arthritis. Completed, enrolled 26 participants across 3 sites.
Detailed Summary
Summary: The investigators propose a randomized controlled open label study of teriparatide in men or women with rheumatoid arthritis and joint erosions. Specifically, the investigators will examine whether teriparatide in combination with a biologic can retard the development of joint erosions. The study will be conducted at Brigham and Women's Hospital Arthritis Center, several Brigham and Women's Hospital Arthritis Center satellite practices, the University of Massachusetts Medical Center, and Massachusetts General Hospital. Hypothesis: The investigators hypothesize that the combination of teriparatide with biologic will be much more effective at retarding erosion progression then a biologic alone.
Study Details
Timeline
Interventions
20 μg, subcutaneous injection, 1 injection per day
1000 mg of calcium citrate
800 IU of Vitamin D
TNF antagonist as prescribed in clinical practice (such as etanercept or adalimumab)